List of Publications using CP 690550 (Axon 1338) purchased from Axon Medchem
(total 15 publication citations listed; updated JUNE-2016)
Caramalho, Iris, et al. "Human regulatory T-cell development is dictated by Interleukin-2 and-15 expressed in a non-overlapping pattern in the thymus." Journal of autoimmunity 56 (2015): 98-110.|
http://www.sciencedirect.com/science/article/pii/S0896841114001668
http://www.tandfonline.com/doi/abs/10.3109/10428194.2014.957204#.V03CUTUrJaQ
http://www.jimmunol.org/content/190/7/3153.short
http://www.bloodjournal.org/content/early/2016/03/21/blood-2015-11-682906.abstract?sso-checked=true
*AS1517499 and CP690550 were purchased from Axon Medchem.
http://press.endocrine.org/doi/abs/10.1210/jc.2012-3475
Mechanistically Probing Lipid-siRNA Nanoparticle-associated Toxicities Identifies Jak Inhibitors Effective in Mitigating Multifaceted Toxic Responses.
W Tao, X Mao, JP Davide, B Ng, M Cai, PA Burke, AB Sachs and L Sapp-Lorenzino. - nature.com.
Mol. Therapy 2011, 19 3, 567–575. doi:10.1038/mt.2010.282
“Default” Generation of Neonatal Regulatory T Cells.
G Wang, Y Miyahara, Z Guo, M Khattar, SM Stepkowski, W Chen.
J. Immunol. 2010, 185 (1), 71-78. [online]
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.
PP Zenatti, D Ribeiro, W Li, L Zuurbier, MC Silva, M Paganin, J Tritapoe, JA Hixon, AB Silveira, BA Cardoso, LM Sarmento, N Correia, ML Toribio, J Kobarg, M Horstmann, R Pieters, SR Brandalise, AA Ferrando, JP Meijerink, SK Durum, JA Yunes & JT Barata
Nature Genetics, 2011, 43(10), 932-939.
Read more: http://www.nature.com/ng/journal/v43/n10/full/ng.924.html
*Ruxolitinib (INCB 018424) or Tasocitinib (CP-690550) (both purchased from Axon Medchem)
Inhibition of the signalling kinase JAK3 alleviates inflammation in monoarthritic rats.
BH Kim, M Kim, CH Yin, JG Jee, C Sandoval, H. Lee, EA Bach, D Hahm, GH Baeg.
Br. J. Pharmacol. 2011, 164 (1), 106-108. DOI: 10.1111/j.1476-5381.2011.01353.x
Development of a High-throughput cell-Based reporter Assay for Screening of JAK3 Inhibitors.
CH Yin, EA Bach, GH Baeg.
J. Biomol. Screen. 2011, 16 (4), 443-449. [online]
Inhibitory effects of the JAK inhibitor CP690, 550 on human CD4+ T lymphocyte cytokine production.
K Migita, T Miyashita, Y Izumi, T Koga, A Komori, Y Maeda, Y. Jiuchi, Y. Aiba, S Yamasaki, A Kawakami, M. Nakamura, H. Ishibashi.
BMC Immunol. 2011, 12, 51. doi:10.1186/1471-2172-12-51
Influence of Janus Kinase Inhibition on Interleukin 6-mediated Induction of Acute-phase Serum Amyloid A in Rheumatoid Synovium.
K Migita, T Koga, A Komori, T Torigoshi, Y Maeda, Y Izumi, J Sato, Y. Jiuchi, T Miyashita, S Yamasaki, A Kawakami, M Nakamura, S Motokawa, H Ishibashi.
J. Rheumatol. 2011, 38 (11), 2309-2317. [online]
Comprehensive analysis of kinase inhibitor selectivity.
MI Davis, JP Hunt, S Herrgard, P Ciceri, LM Wodicka, G Pallares, M Hocker, DK Treiber, PP Zarrinkar.
Nature Biotechnol. 2011, 29, 1046–1051. doi:10.1038/nbt.1990
CP690, 550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes.
K Migita, A Komori, T Torigoshi, Y Maeda, Y Izumi, Y. Jiuchi, T Miyashita, M Nakamura, S Motokawa, H Ishibashi.
Arthritis Res. Therapy 2011, 13:R72. [online]
Kinetics and activation requirements of contact-dependent immune suppression by human regulatory T cells.
M Hagness, K Henjum, J Landskron, KW Brudvik, BA Bjørnbeth, A Foss, K Taskén, EM Aandahl.
J. Immunol. 2012, vol. 188 no. 11 5459-5466. [online]
Interleukin-4 and Prostaglandin E2 Synergistically Up-Regulate 3β-Hydroxysteroid Dehydrogenase Type 2 in Endometrioma Stromal Cells.
Y Urata, Y Osuga, I Akiyama, M Nagai, G Izumi, M Takamura, ... & S Kozuma.
J. Clin. Endocrinol. & Metabo. 2013, 98(4), 1583-1590.
Read more: http://jcem.endojournals.org/content/98/4/1583.short
(This is an incomplete list, updated JUNE-2016)
